PubMed Health⌕ Search

Biomedical subjects

T S Spritzer

Publications and source records attributed to T S Spritzer.

6 recordsLinked to original sources
PubMed1990

[24-hour antihypertensive efficacy of nitrendipine].

PURPOSE: To evaluate the efficacy of nitrendipine 20 mg OD in mild to moderate hypertensive subjects. PATIENTS AND METHODS: Twenty patients followed for 90 days. The protocol was a double blind placebo control trial using 24 hours ambulatory blood pressure monitoring system for pressure and heart rate observations. After 15 days without any drug patients were randomly assigned to the study divided into two subgroups: one remained 30 days using placebo and the other nitrendipine. After a new 15 days washout period there was a cross over of the study groups and then other 30 days of follow-up. RESULTS: The 24 hours mean systolic blood pressure decreased (p less than 0.0001) with nitrendipine (127.7 +/- 8 mmHg) in relation to placebo (139.2 +/- 8 mmHg); the mean diastolic blood pressure decreased (p less than 0.0001) with nitrendipine (84.6 +/- 4 mmHg) in relation to placebo (90.7 +/- 5 mmHg). There were no significant changes on heart rate and body weight. CONCLUSION: Nitrendipine seems to be a safe and efficient antihypertensive agent for 24 hours blood pressure control. The drug can decrease blood pressure levels without significant changes over the circadian pattern of the 24 hours blood pressure curve and without unwanted drop of blood pressure levels.

Ambulatory Care↗
PubMed1989

Treatment of resistant hypertension: 3 years of follow-up with the combination of verapamil and methyldopa.

A combination of verapamil (V), methyldopa (M), and hydrochlorothiazide (H) was tried in hypertensive patients resistant to the usual stepped-care therapy. After at least 60 days with a third-step regimen, placebo was added during the last 2 weeks. Twenty patients whose diastolic blood pressure (DBP) remained greater than 100 mm Hg were assigned to the study. During the initial titration period patients received increasing doses of V (240-480 mg) and M (500-1,500 mg). H was kept at 50 mg/day. Other previously administered drugs were gradually withdrawn. Goal pressure was DBP less than or equal to 95 mm Hg. Follow-up lasted 3 years. Sixteen patients participated in the investigation until the end and all but one reached the goal DBP. Mean systolic BP dropped from 187 +/- 17 to 150 +/- 15 mm Hg (p less than 0.05) and DBP from 118 +/- 12 to 90 +/- 9 mm Hg (p less than 0.01). Adverse effects were rare and mild. Other control measurements did not show any change except improvement of the electrocardiogram of 11 patients, and of the optic fundus of 10 patients. The number of drug unities to be taken dropped from 10 +/- 4 to 7 +/- 2 (p less than 0.05). The abovementioned combination seems to be useful in the control of resistant hypertension. Efficacy was sustained and tolerability was excellent. A potential to reverse target organ damage, namely of the heart and optic fundus, is suggested.

Adult↗